Skip to Content

Arcus Biosciences Inc RCUS

Morningstar Rating
$16.90 −0.56 (3.21%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

RCUS is trading at a 55% premium.
Price
$16.91
Fair Value
$38.55
Uncertainty
Very High
1-Star Price
$44.38
5-Star Price
$55.43
Economic Moat
Thwrn
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RCUS is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$17.46
Day Range
$16.8717.51
52-Week Range
$12.9525.47
Bid/Ask
$16.67 / $20.18
Market Cap
$1.54 Bil
Volume/Avg
525,096 / 740,582

Key Statistics

Price/Earnings (Normalized)
Price/Sales
5.51
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
577

Comparables

Valuation

Metric
RCUS
CLDX
TYRA
Price/Earnings (Normalized)
Price/Book Value
2.173.002.57
Price/Sales
5.51323.22
Price/Cash Flow
Price/Earnings
RCUS
CLDX
TYRA

Financial Strength

Metric
RCUS
CLDX
TYRA
Quick Ratio
5.0731.4413.27
Current Ratio
5.2231.7713.80
Interest Coverage
−135.00
Quick Ratio
RCUS
CLDX
TYRA

Profitability

Metric
RCUS
CLDX
TYRA
Return on Assets (Normalized)
−12.95%−23.59%−21.92%
Return on Equity (Normalized)
−27.45%−25.21%−23.10%
Return on Invested Capital (Normalized)
−33.04%−25.04%−27.33%
Return on Assets
RCUS
CLDX
TYRA
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRXphqqdjkwjSqyr$586.1 Bil
VRTX
Vertex Pharmaceuticals IncMhdjrgjTdmsfg$113.7 Bil
REGN
Regeneron Pharmaceuticals IncLyfggkpCccrsc$108.2 Bil
MRNA
Moderna IncPhwjbbflBndd$50.9 Bil
ARGX
argenx SE ADRRyznprcvYjlch$22.0 Bil
BNTX
BioNTech SE ADRKmxhjmkwDhzj$21.8 Bil
ALNY
Alnylam Pharmaceuticals IncNlscvvlyDdpvzm$18.9 Bil
BMRN
Biomarin Pharmaceutical IncYxhbvnljFtncsd$14.6 Bil
INCY
Incyte CorpPwzxjppkzMjnfvy$12.8 Bil
RPRX
Royalty Pharma PLC Class ACxxzbxkdmmMpwpcj$12.3 Bil

Sponsor Center